These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38050329)

  • 21. Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling.
    Bu F; Cho YS; He Q; Wang X; Howlader S; Kim DH; Zhu M; Shin JG; Xiang X
    Drug Des Devel Ther; 2024; 18():4585-4600. PubMed ID: 39429896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.
    Li T; Zhou S; Wang L; Zhao T; Wang J; Shao F
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):367-384. PubMed ID: 38554227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.
    Kovar C; Loer HLH; Rüdesheim S; Fuhr LM; Marok FZ; Selzer D; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2024 Jul; 13(7):1144-1159. PubMed ID: 38693610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.
    Salerno SN; Edginton A; Gerhart JG; Laughon MM; Ambalavanan N; Sokol GM; Hornik CD; Stewart D; Mills M; Martz K; Gonzalez D;
    Clin Pharmacol Ther; 2021 Jan; 109(1):253-262. PubMed ID: 32691891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
    Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
    AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
    Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.
    Chen Y; Ma F; Jones NS; Yoshida K; Chiang PC; Durk MR; Wright MR; Jin JY; Chinn LW
    CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):332-341. PubMed ID: 32383787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
    Ji T; Chen X; Yeleswaram S
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
    Djebli N; Parrott N; Jaminion F; O'Jeanson A; Guerini E; Carlile D
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):396-409. PubMed ID: 38044486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
    Kollipara S; Ahmed T; Praveen S
    Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
    Zhou D; Podoll T; Xu Y; Moorthy G; Vishwanathan K; Ware J; Slatter JG; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):489-499. PubMed ID: 31044521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.